Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel

被引:24
作者
De Marinis, Filippo [1 ]
Bria, Emilio [2 ]
Baas, Paul [3 ]
Tiseo, Marcello [4 ]
Camerini, Andrea [5 ,6 ]
Favaretto, Adolfo Gino [7 ]
Gridelli, Cesare [8 ]
机构
[1] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[2] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, I-37100 Verona, Italy
[3] Netherlands Canc Inst, Thorac Oncol, Amsterdam, Netherlands
[4] Univ Hosp Parma, Med Oncol, Parma, Italy
[5] Versilia Hosp, Med Oncol, Lido Di Camaiore, Italy
[6] Ist Toscano Tumori, Lido Di Camaiore, Italy
[7] Ist Oncol Veneto IRCCS, Padua, Italy
[8] SG Moscati Hosp, Avellino, Italy
关键词
Chemotherapy; Lung cancer; Review; Treatment; Unfit; RANDOMIZED PHASE-III; COOPERATIVE-ONCOLOGY-GROUP; ELDERLY-PATIENTS; PERFORMANCE STATUS; SINGLE-AGENT; DOSE ADJUSTMENT; CHEMOTHERAPY; CISPLATIN; CARBOPLATIN; TRIAL;
D O I
10.1016/j.cllc.2015.04.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The assessment of special categories of non-small-cell lung cancer (NSCLC) patients requires a comprehensive analysis of all factors potentially influencing the daily quality of life and the relative contribution of tumor-related symptoms on the overall patient health status. While for elderly patients prospective evidence and recommendations allow clinicians to better address their patients to a shared treatment, a paucity of reliable data refers to treatment opportunities for these patients, termed frail or unfit, who are not considered eligible for chemotherapy usually administered to adult patients. This consensus was inspired by the absence of clear criteria to define the category of unfit patients in the context of advanced NSCLC in order to share all the available tools for their classification and evaluation and to support decisions for clinical practice on a daily basis. After review of the literature and panelist consensus, a series of items was identified as relevant: age, performance status, renal function, heart failure, previous cerebrovascular events, uncontrolled hypertension, neuropathy, hearing loss, symptomatic brain metastases, severe psychiatric disorders, and absence of caregiver support. On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatinbased chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy.
引用
收藏
页码:399 / 405
页数:7
相关论文
共 41 条
[1]  
Abe T, 2015, J CLIN ONCOL
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]   Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) [J].
Allemani, Claudia ;
Weir, Hannah K. ;
Carreira, Helena ;
Harewood, Rhea ;
Spika, Devon ;
Wang, Xiao-Si ;
Bannon, Finian ;
Ahn, Jane V. ;
Johnson, Christopher J. ;
Bonaventure, Audrey ;
Marcos-Gragera, Rafael ;
Stiller, Charles ;
Azevedo e Silva, Gulnar ;
Chen, Wan-Qing ;
Ogunbiyi, Olufemi J. ;
Rachet, Bernard ;
Soeberg, Matthew J. ;
You, Hui ;
Matsuda, Tomohiro ;
Bielska-Lasota, Magdalena ;
Storm, Hans ;
Tucker, Thomas C. ;
Coleman, Michel P. .
LANCET, 2015, 385 (9972) :977-1010
[4]  
[Anonymous], P AM SOC CLIN ONCOL
[5]   Geriatric oncology [J].
Balducci, L .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 46 (03) :211-220
[6]  
Balducci L, 2001, Cancer Control, V8, P1
[7]   Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326) [J].
Belani, CP ;
Fossella, F .
CANCER, 2005, 104 (12) :2766-2774
[8]   Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group [J].
Burdett, S. ;
Stephens, R. ;
Stewart, L. ;
Tierney, J. ;
Auperin, A. ;
Le Chevalier, T. ;
Le Pechoux, C. ;
Pignon, J. P. ;
Arriagada, R. ;
Higgins, J. ;
Johnson, D. ;
van Meerbeeck, J. ;
Parmar, M. ;
Souhami, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4617-4625
[9]  
Corre R, 2013, J THORAC ONCOL, V8, pS192
[10]   Non-Small Cell Lung Cancer, Version 1.2015 [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Akerley, Wallace ;
Bazhenova, Lyudmila A. ;
Borghaei, Hossein ;
Camidge, David Ross ;
Cheney, Richard T. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Demmy, Todd L. ;
Dilling, Thomas J. ;
Govindan, Ramaswamy ;
Grannis, Frederic W., Jr. ;
Horn, Leora ;
Jahan, Thierry M. ;
Komaki, Ritsuko ;
Kris, Mark G. ;
Krug, Lee M. ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Lilenbaum, Rogerio ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Martins, Renato ;
Otterson, Gregory A. ;
Patel, Jyoti D. ;
Pisters, Katherine M. ;
Reckamp, Karen ;
Riely, Gregory J. ;
Rohren, Eric ;
Schild, Steven ;
Shapiro, Theresa A. ;
Swanson, Scott J. ;
Tauer, Kurt ;
Yang, Stephen C. ;
Gregory, Kristina ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (12) :1738-1761